In this phase 3 study, researchers sought to determine whether the addition of palbociclib may overcome resistance to endocrine and HER2-directed therapies.
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Sara M. Tolaney, ...
For the new study, researchers recruited 518 patients with advanced triple-positive breast cancer across 109 hospitals in the U.S., Europe, New Zealand and Australia between June 2017 and July 2021.
MRI concentric partial response pattern as a predictor of pathological complete response in early triple-negative breast cancer treated with Keynote-522 neoadjuvant therapy. This is an ASCO Meeting ...
—Building off of earlier findings, researchers sought to determine rates of neoadjuvant systemic therapy (NST) among U.S. women with cT1–2 N0 M0 HER2-positive breast cancer and identify factors ...
Tenth Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca’s ENHERTU with the latest based on DESTINY-Breast05 phase 3 trial results Sixteenth Breakthrough Therapy Designation granted ...
Life brings about normal ups and downs. Through connection with a professional, clarity and relief can be found. Whether it be intrinsic indicators (mind/body) or external forces that have led to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results